Kodiak’s tarcocimab tedromer program, branded as Zenkuda, delivered a Phase 3 win in diabetic retinopathy in the Glow2 trial, beating a sham procedure. The company plans to move quickly toward an accelerated multi-indication BLA submission, following prior setbacks that had held back investor confidence. The article provides a key efficacy signal: 62.5% of treated patients achieved at least a two-step improvement in diabetic retinopathy severity score versus 3.3% in the sham group. The readout also supports a formulation strategy connected to Kodiak’s antibody biopolymer conjugate (ABC) platform, with potential read-throughs for future IL-6/VEGF-targeted bispecifics. The update is a major valuation driver for an ophthalmology-focused biotech and sets up a pivotal regulatory and commercialization path as competing ocular immunotherapies vie for expanded late-stage positioning.